Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Close

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
The Journal of Pathology|March 1, 1996
An immunohistochemical study of TAL-1 protein expression in leukaemias and lymphomas with a novel monoclonal antibody, 2TL 242R Chetty, K Pulford, M Jones, et al.
European Heart Journal|November 1, 1995
Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled studyJ P Herrman, R Simon, V A Umans, et al.
Leukemia & Lymphoma|March 1, 1997
Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virusL Leoncini, D Spina, P Close, et al.
The New England Journal of Medicine|November 14, 1997
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacementB I Eriksson, P Wille-Jørgensen, P Kälebo, et al.
Leukemia & Lymphoma|June 1, 1996
Abortive mitoses and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's diseaseL Leoncini, D Spina, P Close, et al.
Clinical Pharmacology and Therapeutics|July 1, 1997
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudinG Lefèvre, M Duval, S Gauron, et al.
The Journal of Trauma|August 9, 2001
Liberalized screening for blunt carotid and vertebral artery injuries is justifiedA J Kerwin, R P Bynoe, J Murray, et al.
Cell Death and Differentiation|February 4, 2014
MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradationK Shostak, F Patrascu, S I Göktuna, et al.
Brain : a Journal of Neurology|February 1, 1986
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?J M Allen, A J Cross, J C Yeats, et al.
Circulation|November 1, 1993
Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplastyA A van den Bos, J W Deckers, G R Heyndrickx, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The Journal of Pathology|March 1, 1996
An immunohistochemical study of TAL-1 protein expression in leukaemias and lymphomas with a novel monoclonal antibody, 2TL 242R Chetty, K Pulford, M Jones, et al.
European Heart Journal|November 1, 1995
Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled studyJ P Herrman, R Simon, V A Umans, et al.
Leukemia & Lymphoma|March 1, 1997
Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virusL Leoncini, D Spina, P Close, et al.
The New England Journal of Medicine|November 14, 1997
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacementB I Eriksson, P Wille-Jørgensen, P Kälebo, et al.
Leukemia & Lymphoma|June 1, 1996
Abortive mitoses and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's diseaseL Leoncini, D Spina, P Close, et al.
Clinical Pharmacology and Therapeutics|July 1, 1997
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudinG Lefèvre, M Duval, S Gauron, et al.
The Journal of Trauma|August 9, 2001
Liberalized screening for blunt carotid and vertebral artery injuries is justifiedA J Kerwin, R P Bynoe, J Murray, et al.
Cell Death and Differentiation|February 4, 2014
MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradationK Shostak, F Patrascu, S I Göktuna, et al.
Brain : a Journal of Neurology|February 1, 1986
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?J M Allen, A J Cross, J C Yeats, et al.
Circulation|November 1, 1993
Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplastyA A van den Bos, J W Deckers, G R Heyndrickx, et al.
Pageof 9